Journal of Geriatric Cardiology 2011/8:2 PP.88-92
Background To document the pharmacotherapy of chronic heart failure (CHF) and to evaluate the adherence to treatment guidelines in Australian population. Methods The pharmacological management of 677 patients (female 46.7%, 75.5 ± 11.6 years) with CHF was retrospectively analyzed. Results The use of angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) and β-blockers were 58.2 % and 34.7 %, respectively. Major reasons for non-use of ACE inhibitors/ARBs were hyperkalemia and elevated serum creatinine level. For patients who did not receive β-blockers, asthma and chronic obstructive pulmonary disease were the main contraindications. Treatment at or above target dosages for ACE inhibitors/ARBs and β-blockers was low for each medication (40.3% and 28.9%, respectively). Conclusions Evidenced-based medical therapies for heart failure were under used in a rural patient population. Further studies are required to develop processes to improve the optimal use of heart failure medications.
1 McLean AS, Eslick GD, Coats AJ. The epidemiology of heart failure in Australia. Int J Cardiol 2007; 118(3): 370-374.
2 Krum H, Tonkin AM, Currie R, et al. Chronic heart failure in Australian general practice: the Cardiac Awareness Survey and Evaluation (CASE) study. Med J Aust 2001; 174(9): 439-444.
3 He SW, Wang LX. Impact of anaemia on the outcomes of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail 2009; 15(3): 123-130.
4 Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: Survival trends in 12,220 index admissions in Leicestershire 1993-2001. Heart 2003(6); 89: 615-620.
5 Krum H, Jelinek MV, Stewart S, et al. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust 2006; 185(10): 549-556.
6 Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2005; 112(12): e154-235.
7 Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin- converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362(9386): 772-776.
8 Störk S, Hense HW, Zentgraf C, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: A prospective cohort study. Eur J Heart Fail 2008; 10(12): 1236-1245.
9 Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005; 26(16): 1653-1659.
10 Clark RA, Eckert KA, Stewart S, et al. Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study. Med J Aust 2007; 186(9): 441-445.
11 Granmyr J, Ball P, Curran S, et al. Evidence-based management of CAD in a rural community. Aust J Rural Health 2007; 15(4): 241-246.
12 Wang L, Curran S, Ball P, et al. Pharmacotherapy for atrial fibrillation in elderly hospitalized patients with comorbid congestive heart failure in Australia: a retrospective study. Cur Ther Res 2008; 69(6): 514-524.
13 Tang TH, Hung J, Finn J. The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia. Med J Aust 2010; 192(6): 306-310.
14 Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19): 2388-2442.
15 Arif SA, Mergenhagen KA, Del Carpio RO, et al. Treatment of systolic heart failure in the elderly: an evidence-based review. Ann Pharmacother 2010; 44(10): 1604-1614.
16 Koschack J, Jung HH, Scherer M, et al. Prescriptions of recommended heart failure medications can be correlated with patient and physician characteristics. Int J Clin Pract 2009; 63(2): 226-232.
17 Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24(5): 464-474.
18 Krum H. Consider β-blockers with heart failure. BMJ 2009; 338: b1728.
19 Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667-1675.
20 Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893-1906.
21 Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010; 122(6): 585-596.